Target Discovery and Development Network (TDDN)
Recent progress in the development of multi-dimensional characterization data sets that compare tumor and normal tissue genomes from the same individual has led to unprecedented detail of the molecular alterations that serve as driver mutations that lead to cancer. The integration of these data sets with biological information from basic research is providing new directions for developing treatment strategies that target the specific molecular changes in a patient’s disease, moving away from a one-size-fits all approach. Recent findings from the The Cancer Genome Atlas, Therapeutically Applicable Research to Generate Effective Targets programs and other large scale cancer genomic studies are already identifying new targets for cancer therapeutic and diagnostic interventions. These data sets are ready to be incorporated into molecular target discovery and validation programs.
Five projects have been chosen as part of a program supported by the American Recovery and Reinvestment Act Grand Opportunities Program (RFA-OD-09-004), to focus on the development of novel approaches to:
- Molecular target validation
- Identification of targets and biomarkers from multi-dimensional cancer genomic data sets
- Chemical genomics that emphasizes the most challenging targets
- Small molecule screening
The following groups have been selected as molecular TDDN Centers:
| Project Title: |
A Concerted Attack on Patient Specific Oncogenic Vulnerabilities in Lung Cancer |
| Affiliation: |
University of Texas Southwestern Medical Center, Dallas, Texas |
| Principal Investigator: |
Michael Roth, Ph.D. |
| Project Title: |
Cold Spring Harbor Laboratory Molecular Target Discovery and Development Center |
| Affiliation: |
Cold Spring Harbor Laboratory, Long Island, N.Y. |
| Principal Investigator: |
Scott Powers, Ph.D. |
| Project Title: |
Functional Annotation of Cancer Genomes: TCGA, Glioblastoma and Ovarian Cancer |
| Affiliation: |
Dana-Farber Cancer Institute, Boston, Mass. |
| Principal Investigator: |
William Hahn, M.D., Ph.D., Lynda Chin, M.D. and Ronald DePinho, M.D. |
| Project Title: |
Systems Biology of Tumor Progression and Drug Resistance |
| Affiliation: |
Columbia University, New York, N.Y. |
| Principal Investigator: |
Andrea Califano, Ph.D. |
| Project Title: |
Targeting Causal Cancer Genes with Small Molecules |
| Affiliation: |
The Broad Institute, Cambridge, Mass. |
| Principal Investigator: |
Stuart Schreiber, Ph.D. |
View a map of the TDDN Centers 
Back to Top
